Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...

Company Deals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Fineline Cube Jan 6, 2025

China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...

Company Medical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Fineline Cube Jan 6, 2025

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...

Company Drug

Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA

Fineline Cube Jan 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial

Fineline Cube Jan 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...

Policy / Regulatory

China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027

Fineline Cube Jan 6, 2025

China’s State Council has released the “Opinions on Fully Deepening the Reform of Drug and...

Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

Fineline Cube Jan 5, 2025

Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...

Company Drug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

Fineline Cube Jan 3, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...

Company Drug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...

Company Drug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

Fineline Cube Jan 3, 2025

US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...

Company Drug

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

Fineline Cube Jan 3, 2025

China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

Shanghai Enacts New Regulations for Drug and Medical Device Administration

Fineline Cube Jan 3, 2025

The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...

Company Drug

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Fineline Cube Jan 3, 2025

Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...

Company Deals

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

Fineline Cube Jan 3, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...

Company Drug

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

Fineline Cube Jan 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...

Company Drug

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Fineline Cube Jan 3, 2025

Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...

Company Drug

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Medical Device

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment

Fineline Cube Jan 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...

Company Drug

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

Fineline Cube Jan 3, 2025

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received...

Posts pagination

1 … 258 259 260 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.